76
Participants
Start Date
October 31, 2009
Primary Completion Date
March 31, 2011
Study Completion Date
March 31, 2011
Tosedostat
"In Part A, approximately 70 subjects will be randomized to one of 2 dose regimens of tosedostat which will be administered orally, once daily. The dose regimens of tosedostat will be:~* 120 mg for 6 months once daily, OR~* 240 mg (induction dose) once daily for 2 months, followed by 120 mg(maintenance dose) for 4 months~In Part B a further 130 subjects will receive the dose regimen of tosedostat identified in Part A as being appropriate, based on the interim analysis during Part A."
Memorial Sloan-Kettering Cancer Center, New York
Weill Cornell Medical College - New York Presbyterian Hospital, New York
Montefiore Medical Center Weiler Division, The Bronx
Monter Cancer Center, Lake Success
Washington Cancer Institute, Washington D.C.
Duke Univeristy Medical Center, Durham
Emory University Clinic, Atlanta
M.D. Anderson Cancer Center Orlando, Orlando
Taussig Cancer Institute, Cleveland
University of Chicago Medical Center, Chicago
Washington University, Oncology/Bone Marrow Transplant, St Louis
MD Anderson Cancer Center, Houston
UCLA School of Medicine, Los Angeles
University of Michigan Health System, Ann Arbor
John Theurer Cancer Center, Hackensack University Medical Center,, Hackensack
Stony Brook University Medical Center, Stony Brook
Froedtert Hospital, Milwaukee
Princess Margaret Hopsital, Toronto
Royal Victoria Hospital, Montreal
VUMC, Amsterdam
Erasmus MC, Rotterdam
Lead Sponsor
Quintiles, Inc.
INDUSTRY
Chroma Therapeutics
INDUSTRY